Table 2.
Two-year primary, secondary and tertiary outcomes in patients from non-Asian and Asian countries.
|
Events, n (%)a |
Adjusteda HR(95% CI) | pa | Fully adjustedb HR(95% CI) | pb | ||
|---|---|---|---|---|---|---|
| Non-Asian(n = 16,922) | Asian(n = 2178) | |||||
| Primary outcome | ||||||
| MACE | 1740 (10.5) | 224 (11.1) | 1.06 (0.92–1.22) | 0.39 | 1.02 (0.89–1.18) | 0.74 |
| Non-fatal myocardial infarction | 214 (1.3) | 16 (0.8) | 0.63 (0.38–1.05) | 0.07 | 0.63 (0.37–1.05) | 0.07 |
| Non-fatal stroke | 1289 (7.8) | 173 (8.5) | 1.09 (0.93–1.28) | 0.27 | 1.07 (0.91–1.26) | 0.38 |
| Cardiovascular death | 301 (1.8) | 43 (2.3) | 1.27 (0.92–1.75) | 0.14 | 1.11 (0.80–1.54) | 0.52 |
| Secondary outcomes | ||||||
| All-cause death | 820 (4.9) | 102 (5.3) | 1.08 (0.88–1.33) | 0.45 | 0.98 (0.79–1.21) | 0.87 |
| Myocardial infarction | 221 (1.4) | 17 (0.9) | 0.65 (0.39–1.06) | 0.08 | 0.64 (0.38–1.05) | 0.07 |
| Stroke | 1298 (7.9) | 176 (8.7) | 1.11 (0.94–1.29) | 0.21 | 1.09 (0.92–1.28) | 0.31 |
| Intracranial haemorrhage | 192 (1.3) | 45 (2.4) | 1.88 (1.36–2.61) | <0.001 | 1.87 (1.34–2.60) | <0.001 |
| Bleeding | 2238 (14.7) | 304 (16.0) | 1.10 (0.98–1.24) | 0.12 | 1.08 (0.95–1.23) | 0.20 |
| Minor bleeding | 1753 (11.6) | 224 (11.9) | 1.03 (0.90–1.19) | 0.66 | 1.02 (0.88–1.17) | 0.84 |
| Major bleeding | 606 (4.1) | 98 (5.4) | 1.33 (1.08–1.65) | 0.008 | 1.30 (1.04–1.61) | 0.02 |
| Tertiary outcomes | ||||||
| New-onset atrial fibrillation | 390 (2.4) | 33 (1.8) | 0.75 (0.53–1.07) | 0.12 | 0.84 (0.58–1.19) | 0.32 |
| MACEc | 69 (18.4) | 6 (18.3) | 0.92 (0.39–2.14) | 0.99 | 0.98 (0.42–2.30) | .96 |
CI: confidence interval; HR: hazard ratio; MACE: major adverse cardiovascular events.
aAdjusted for age and sex.
bAdjusted for age, sex, modified Rankin Scale, hypertension, statin use and antiplatelet treatment allocation (aspirin or terutroban).
cCalculated for patients with new onset atrial fibrillation.